Twist Bioscience Corporation (TWST) rises on deep earnings analysis
Twist Bioscience Corporation (TWST) rose after a mixed quarter that featured an EPS miss but a revenue beat, continued sequential growth, and improving segment momentum. This deep dive examines the margin expansion, adjusted EBITDA breakeven path, and why investors focused on the bigger operating picture.
Twist Bioscience Corporation (NASDAQ: TWST) rose 8.44% after fiscal second-quarter revenue of $110.7 million topped estimates, even though EPS missed expectations at -$0.56. Investors focused on 13 straight quarters of sequential revenue growth, 28% growth in DNA synthesis and Protein Solutions, and management’s reaffirmed path to adjusted EBITDA breakeven in fiscal Q4 2026.
Twist Bioscience Corporation (TWST) shares rise 8.44% to $99.28 after the company reported fiscal second-quarter revenue of $0.12B, above the $0.11B estimate. The headline was mixed: EPS came in at -$0.56 versus an estimated -$0.49333, but revenue growth, segment momentum, and the path toward adjusted EBITDA breakeven supported the market reaction.
Key Takeaways
TWST earnings showed a revenue beat but an EPS miss. Revenue reached $0.12B against a $0.11B estimate, while EPS was -$0.56 versus -$0.49333.
The company posted its 13th consecutive quarter of sequential revenue growth. CEO Emily Leproust said fiscal second-quarter revenue reached $110.7M, up more than 19% year over year.
DNA synthesis and Protein Solutions grew 28%, supported by AI-enabled drug discovery. NGS applications grew 12% year over year and 9% sequentially.
Management said margin expanded above 50% and reaffirmed that Twist remains on track for adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
Amazon Web Services named Twist as a wet lab partner for Amazon BioDiscovery, adding a high-profile validation for the company’s DNA synthesis, protein solutions, and biologics capabilities.
Analyst sentiment remains constructive. The consensus rating is Buy, based on 11 Buy ratings, 2 Holds, and 1 Sell. Recent actions included a Canaccord Genuity target increase to $120 and an Evercore ISI downgrade to In-Line with its target raised to $102.
TWST Earnings: Financial Performance and Segment Trends
The fiscal second-quarter result extends a steady top-line climb. Quarterly revenue was $0.10B for the period ended Sept. 30, 2025, $0.10B for the period ended Dec. 31, $0.11B for the period ended March 31, 2026, and $0.12B for the period ended June 30, 2026. That sequence gives the company a clear record of sequential expansion, even as profitability remains the more difficult part of the story.
The revenue result exceeded the $0.11B consensus estimate. EPS, however, missed the -$0.49333 estimate with a loss of -$0.56. The loss was better than the prior quarter’s -$0.71 EPS, but it remained weaker than the -$0.50 reported for the December quarter and the -$0.45 reported for the September quarter. The year-ago quarter produced EPS of $0.34, making the recent return to losses an important point for investors tracking the company’s operating leverage.
Net income was -$0.04B in the June quarter, matching the March quarter’s -$0.04B loss. Net income was -$0.03B in both the December and September quarters. The comparison shows that revenue has continued to move higher while the bottom line has not yet matched that progress. Twist’s adjusted EBITDA breakeven target therefore carries more weight than the quarterly EPS figure alone.
Twist described the quarter through two major growth groupings. DNA synthesis and Protein Solutions grew 28% year over year, while NGS applications grew 12% year over year and 9% sequentially. The NGS rebound matters because the segment had grown more slowly in the recent period. A 9% sequential gain gives the company a second growth engine alongside its expanding discovery work.
The last detailed annual segment breakout, for the fiscal year ended Sept. 30, 2025, listed NGS Tools revenue of $208,104,000 and Synthetic Genes revenue of $113,602,000. Antibody Discovery contributed $23,452,000, Oligo Pools contributed $20,230,000, and DNA and Biopharma Libraries contributed $11,184,000. Those figures show why NGS and synthetic genes remain central to the company’s revenue base, while newer protein and discovery offerings add room for product expansion.
Margin performance provided another positive signal. Leproust said Twist had expanded margin above 50%. The company did not pair that statement with a detailed margin figure in the available remarks, so the central point is direction rather than a precise quarterly margin comparison. Revenue growth above 19% and margin expansion together support the operating leverage case, but the -$0.56 EPS result shows that the transition still carries execution risk.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Market Reaction and Analyst Response to TWST Earnings
TWST traded at $99.28 during the regular session on Aug. 3, 2026, up 8.44%. Volume reached 2,205,682 shares against an average of 1,721,169. The combination of a strong price move and above-average volume shows that the revenue beat and forward profitability message outweighed the EPS miss in the session’s trading.
The analyst backdrop entering the report was positive but not uniform. Canaccord Genuity maintained a Buy rating on July 14 and raised its price target from $90 to $120. Guggenheim maintained Buy with a $107 target, while Barclays maintained Overweight with a $95 target and TD Cowen maintained Buy with an $89 target.
Evercore ISI took a more cautious stance on July 6, downgrading Twist from Outperform to In-Line. However, Evercore also raised its target from $66 to $102. That combination captures the central tension in the TWST earnings analysis: analysts can recognize stronger business execution while still questioning how much of that progress is already reflected in the stock.
Leerink Partners upgraded Twist from Market Perform to Outperform on May 5 and set a $70 target. The current consensus remains Buy, with 11 Buy ratings, 2 Holds, and 1 Sell. Recent targets from $89 to $120 show broad support for the growth thesis, although the spread also reflects different views on valuation and the timing of profitability.
Management Commentary: Platform Scale and Profitability
"Twist delivered another strong quarter and extended our track record of consistent execution, posting our 13th quarter of sequential revenue growth." - Emily Leproust, CEO and Co-Founder, TWST earnings call
Leproust’s strategic message centered on the company’s semiconductor-based DNA platform. She said the platform gives Twist structural advantages in cost, scale, and speed. It also supports faster product launches because the same manufacturing base can serve synthetic genes, protein solutions, biologics, and NGS products.
That platform argument received a concrete commercial example through Amazon Web Services. Twist is working with AWS on Amazon BioDiscovery, an AI-powered drug discovery application. The company also cited work with Memorial Sloan Kettering Cancer Center and GRAIL as scientific launch partners. The strategic value is straightforward: AI can create more designs, but customers still need physical synthesis, testing, and validation.
"We remain firmly on track to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026." - Emily Leproust, CEO and Co-Founder, TWST earnings call
This is the most important financial guidance in the available TWST earnings call remarks. The company’s revenue growth is already visible in the quarterly figures. The breakeven target provides the test for whether that growth can translate into a more durable earnings profile.
"More sequences accepted means more orders won and we intend to win them." - Patrick Finn, President and COO, TWST earnings call
Finn connected manufacturing improvements to market share. Twist said it currently accepts about 97% of clonal genes and about 99% of DNA requests more broadly. The company announced a goal of accepting approximately 99.5% of clonal genes and 99.9% of all DNA products more broadly. In plain English, the company is trying to reduce the number of orders that customers send elsewhere because one difficult sequence cannot be manufactured.
The strategy also explains why management emphasizes breadth. Customers can use Twist for pooled libraries, clonal genes, protein expression, antibodies, and NGS workflows. A broader product range gives the company more opportunities to capture spending from each customer relationship, while the shared DNA platform supports cost and speed across those offerings.
Bottom Line
TWST earnings delivered the combination the market rewarded: revenue above consensus, double-digit growth across key offerings, and a stated path to adjusted EBITDA breakeven in fiscal fourth quarter 2026. The -$0.56 EPS miss and continuing net loss still matter, so the stock’s next phase depends on whether margin expansion turns the company’s platform growth into sustained profitability.
+Why did Twist Bioscience stock rise after earnings?
Twist Bioscience shares rose because revenue came in above expectations at about $110.7 million versus the $110 million estimate, and management highlighted continued growth and margin expansion. The market looked past the EPS miss because the company also said it remains on track for adjusted EBITDA breakeven in fiscal Q4 2026.
+Did Twist Bioscience beat or miss earnings this quarter?
Twist Bioscience beat on revenue but missed on EPS. Revenue was $0.12 billion versus the $0.11 billion estimate, while EPS was -$0.56 compared with the expected -$0.49333.
+How is Twist Bioscience growing by segment?
DNA synthesis and Protein Solutions grew 28% year over year, while NGS applications rose 12% year over year and 9% sequentially. The company said this was its 13th consecutive quarter of sequential revenue growth.
+What is Twist Bioscience's outlook after this earnings report?
Management reaffirmed that Twist remains on track to reach adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. The company also said margin expanded above 50%, which supports the case for improving operating leverage even though GAAP profitability is still negative.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on TWST?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
